Project: Ghana Emergency Medicine Collaborative
Document Title: Inotropes and Vasoactives
Author(s): Robert Preston (Unive...
Attribution Key
for more information see: http://open.umich.edu/wiki/AttributionPolicy

Use + Share + Adapt
{ Content the ...
Inotropes and Vasoactives	

Robert Preston, MD
Division of Burn, Trauma and Critical Care
Division of Emergency Medicine
U...
Objectives	

•  Review factors central to cardiac output
•  Review physiology and receptors used by
inotropic and vasoacti...
Physiology	

•  Vasopressor = Vasoconstriction
•  Goal: Re-establish blood flow to organs
•  Vasopressors are NOT a volume...
Physiology	

•  Sometimes, you need a drug that
increases cardiac output without
necessarily increasing blood pressure
–  ...
Cardiac Output	

•  Cardiac Output (Q) = HR x SV
•  Heart rate
–  Chronotropism: increase in HR decreases
filling time, in...
Cardiac Output	

•  Preload
–  Volume of venous return that dictates cardiac
output via the Frank-Starling Curve
–  How to...
Cardiac Output	

•  Afterload
–  The impedance to ventricular ejection
–  The factor in the equation that, when
reduced, w...
Cardiac Output	

Inotropism
Increase in force and velocity of contraction

Lusitropism
Promoting diastolic relaxation to i...
Cardiac Output	

Inotropism
Increase in force and velocity of contraction

Lusitropism
Promoting diastolic relaxation to i...
Understanding Receptors	

•  α-adrenergic receptors
•  β-adrenergic receptors
•  Dopaminergic receptors
•  Vasopressin rec...
Understanding Receptors	


Source Undetermined

13
Understanding Receptors	

•  α1-adrenergic receptors
–  Post-synaptic – constricts VSM

•  Debates:
–  Existence of both α...
Understanding Receptors	

•  α2-adrenergic receptors
–  Pre- and post-synaptic
•  Post-synaptic – constricts VSM (as for α...
Understanding Receptors	

•  β1-adrenergic receptors
–  Receptors predominate in the myocardium
–  + rate, + contractility...
Understanding Receptors	

•  Dopaminergic Receptors
–  Re: Dopamine is a precursor of NE and EPI
–  Two major DA receptors...
Understanding Receptors	

•  Vasopressin Receptors
–  V1R – Vasoconstrict vascular smooth muscle
–  V2R – Anti-diuretic ef...
FINALLY!
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
GEMC- Inotropes and Vasoactives- Resident Training
Upcoming SlideShare
Loading in …5
×

GEMC- Inotropes and Vasoactives- Resident Training

606 views
467 views

Published on

This is a lecture by Dr. Robert Preston from the Ghana Emergency Medicine Collaborative. To download the editable version (in PPT), to access additional learning modules, or to learn more about the project, see http://openmi.ch/em-gemc. Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Share Alike-3.0 License: http://creativecommons.org/licenses/by-sa/3.0/.

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
606
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
21
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

GEMC- Inotropes and Vasoactives- Resident Training

  1. 1. Project: Ghana Emergency Medicine Collaborative Document Title: Inotropes and Vasoactives Author(s): Robert Preston (University of Utah), MD 2012 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Share Alike-3.0 License: http://creativecommons.org/licenses/by-sa/3.0/ We have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your ability to use, share, and adapt it. These lectures have been modified in the process of making a publicly shareable version. The citation key on the following slide provides information about how you may share and adapt this material. Copyright holders of content included in this material should contact open.michigan@umich.edu with any questions, corrections, or clarification regarding the use of content. For more information about how to cite these materials visit http://open.umich.edu/privacy-and-terms-use. Any medical information in this material is intended to inform and educate and is not a tool for self-diagnosis or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition. Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers. 1 1
  2. 2. Attribution Key for more information see: http://open.umich.edu/wiki/AttributionPolicy Use + Share + Adapt { Content the copyright holder, author, or law permits you to use, share and adapt. } Public Domain – Government: Works that are produced by the U.S. Government. (17 USC § 105) Public Domain – Expired: Works that are no longer protected due to an expired copyright term. Public Domain – Self Dedicated: Works that a copyright holder has dedicated to the public domain. Creative Commons – Zero Waiver Creative Commons – Attribution License Creative Commons – Attribution Share Alike License Creative Commons – Attribution Noncommercial License Creative Commons – Attribution Noncommercial Share Alike License GNU – Free Documentation License Make Your Own Assessment { Content Open.Michigan believes can be used, shared, and adapted because it is ineligible for copyright. } Public Domain – Ineligible: Works that are ineligible for copyright protection in the U.S. (17 USC § 102(b)) *laws in your jurisdiction may differ { Content Open.Michigan has used under a Fair Use determination. } Fair Use: Use of works that is determined to be Fair consistent with the U.S. Copyright Act. (17 USC § 107) *laws in your jurisdiction may differ Our determination DOES NOT mean that all uses of this 3rd-party content are Fair Uses and we DO NOT guarantee that your use of the content is Fair. 2 To use this content you should do your own independent analysis to determine whether or not your use will be Fair.
  3. 3. Inotropes and Vasoactives Robert Preston, MD Division of Burn, Trauma and Critical Care Division of Emergency Medicine University of Utah Robworldwide@Gmail.com 3
  4. 4. Objectives •  Review factors central to cardiac output •  Review physiology and receptors used by inotropic and vasoactive drugs •  Review different types of inotropic and vasoactive drugs 4
  5. 5. Physiology •  Vasopressor = Vasoconstriction •  Goal: Re-establish blood flow to organs •  Vasopressors are NOT a volume substitute 5
  6. 6. Physiology •  Sometimes, you need a drug that increases cardiac output without necessarily increasing blood pressure –  Inotropic agents –  Vasoconstrictors –  Both 6
  7. 7. Cardiac Output •  Cardiac Output (Q) = HR x SV •  Heart rate –  Chronotropism: increase in HR decreases filling time, increases O2 consumption –  Nature of HR important •  Stroke volume –  Contractility (inotropic state of the myocardium) –  preload and afterload dependent 7
  8. 8. Cardiac Output •  Preload –  Volume of venous return that dictates cardiac output via the Frank-Starling Curve –  How to increase? •  Fluid boluses •  increasing venous tone 8
  9. 9. Cardiac Output •  Afterload –  The impedance to ventricular ejection –  The factor in the equation that, when reduced, will increase the cardiac output •  Measured (MAP) or calculated (SVR) –  Becomes the dominant factor in determining cardiac output when contractility of the heart is impaired* 9
  10. 10. Cardiac Output Inotropism Increase in force and velocity of contraction Lusitropism Promoting diastolic relaxation to improve filling and coronary perfusion 10
  11. 11. Cardiac Output Inotropism Increase in force and velocity of contraction Lusitropism Promoting diastolic relaxation to improve filling and coronary perfusion GOAL: IMPROVE CARDIAC FUNCTION 11
  12. 12. Understanding Receptors •  α-adrenergic receptors •  β-adrenergic receptors •  Dopaminergic receptors •  Vasopressin receptors 12
  13. 13. Understanding Receptors Source Undetermined 13
  14. 14. Understanding Receptors •  α1-adrenergic receptors –  Post-synaptic – constricts VSM •  Debates: –  Existence of both α1a and α1v? –  α1 receptors located in the heart? 14
  15. 15. Understanding Receptors •  α2-adrenergic receptors –  Pre- and post-synaptic •  Post-synaptic – constricts VSM (as for α1) •  Pre-synaptic – inhibit NE release into synaptic cleft •  More α2 receptors in the venous system –  Central actions •  Decrease SNS, Increase PSNS 15
  16. 16. Understanding Receptors •  β1-adrenergic receptors –  Receptors predominate in the myocardium –  + rate, + contractility, + conduction velocity –  Equally sensitive to EPI and NE •  β2-adrenergic receptors –  Mainly located in smooth muscles of blood vessels and bronchus –  More sensitive to EPI than NE 16
  17. 17. Understanding Receptors •  Dopaminergic Receptors –  Re: Dopamine is a precursor of NE and EPI –  Two major DA receptors –  DA1 receptors •  mainly post-synaptic on renal sm and mesentery •  Vasodilation and increased blood flow –  DA2 receptors •  Pre-synaptic: inhibit NE release •  Post-synamptic: vasoconstriction 17
  18. 18. Understanding Receptors •  Vasopressin Receptors –  V1R – Vasoconstrict vascular smooth muscle –  V2R – Anti-diuretic effects –  V3R - ACTH release from pituitary –  OTR – Vasodilation 18
  19. 19. FINALLY!

×